Rapid Testing - Eveia is developing a proprietary revolutionary system, based on ArcFlow technology, that eliminates the need for instrumentation, and provides simple, cost effective, easily interpreted results that are either quantitative or qualitative. Products for in vitro diagnostic use are in development for the Point-of-Care market (physician office, retail clinics, hospitals, clinical laboratories and at-home disease management).

Virtually all disposable Point-of-Care and At-Home diagnostic testing systems are qualitative (yes/no result) and it often proves to be very difficult to interpret a result. Some manufacturers offer electronic instrumentation to aid in interpretation of results or to run the tests and provide quantitative results.  These instruments are often expensive, challenging to use, and require maintenance and significant training.

Product Technology Market Anticipated Release Anemia Alert Patent Pending Cell Quantitation Clinic, Promotional, Home Health, OTC  Q1 2011 ProTrac Coag Patent Pending ArcFlow Coagulation Clinic, Hospital, Home Health  Q2 2011 ProTrac CRP Patent Pending ArcFlow Immunochemistry Clinic, Home Health 2012 ProTrac Infectious Disease Patent Pending ArcFlow Immunochemistry Public Health 2012 Technology Licensing ArcFlow Technology In vitro Diagnostics Manufacturers Ongoing

The technology is unique and will provide freedom to operate, a very valuable attribute in this challenging market that will also provide substantial licensing opportunities for the company.

Rapid Testing - In contrast to current lateral flow devices, Eveia’s Point-of-Care devices rely on changes in flow rate as an analytical tool.  This innovation effectively translates certain properties in composition of the sample into visually discernible differences in the distance migrated, as a measure of that property on a scale like a thermometer, obviating the need for an external instrument.  Eveia’s ArcFlow devices take advantage of this core innovation. Each individual test expands upon this innovation to allow us to analyze a wide variety of specific clinical manifestations. Similar to other POC devices on the market, Eveia’s products are comprised of a plastic case enclosing a test device. The housing protects and binds the components of the test device together, and provides a controlled means for the sample application. The device cover includes indicator markings, directions for use, and branding.  A significant advantage of our design is that the devices are comprised of laminated plastic and paper sheets instead of injection-molded or cast parts, resulting in significant cost savings both in manufacturing and development.  There are currently two patents pending around this technology.

Both figures depict devices from a top down view with the cover remove.  The Anemia Alert hemoglobin device is on the left with the ArcFlow device on the right.  Blood is delivered into the proximal well “A” (Arrow “X”).  Adhesion properties pull the blood into the tapered volumetric capillary reservoir “B” (Arrow “Y”) and onto the underside of the vertical separator “C”.  From the vertical separator, blood is pulled up through capillary and bulk-flow properties onto the indicator strip (lateral separation paper) “D” (Arrow “Z”) and migrates down the indicator strip. Excess volume is collected in “E” of the Anemia Alert device (the distal end of the Indicator strip) until saturation of the paper is reached and no further blood migration can occur. In the ArcFlow device, fluid migration ceases when the sample converges at the distal end of the strip.